TMEM108

Across TCGA pan-cancer cohorts, TMEM108 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM108 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TMEM108 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM108 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

CESC, OV, and LIHC are the cancer types where TMEM108 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.192	0.798	<.001	30	view →
OV	OS	Median	All	0.330	0.841	.040	12	view →
LIHC	DFS	Median	All	0.049	0.556	<.001	12	view →
UCEC	OS	Median	All	1.000	0.653	.024	8	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
LUSC	DFS	Median	All	1.000	0.653	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM108–CESC (OS)

Open the CESC breakdown →